澳大利亚65岁及以上成年人带状疱疹疫苗接种的预测因素
该研究基于2019至2020年开展的三项在线横断面调查,分析澳大利亚65岁及以上成年人带状疱疹疫苗接种率及接种障碍。744名参与者中32%报告接种过带状疱疹疫苗,65-74岁、75-84岁和85岁及以上人群接种率分别为23%、55%和0%。接种流感疫苗或肺炎球菌疫苗者及有卒中史者更可能接种带状疱疹疫苗,每日吸烟者、偏好自然免疫者及不信任疫苗者接种可能性较低。
要点
- 744名65岁及以上澳大利亚成年人中32%报告接种过带状疱疹疫苗。
- 65-74岁、75-84岁和85岁及以上人群接种率分别为23%、55%和0%。
- 接种流感疫苗(OR=4.41)和肺炎球菌疫苗(OR=4.43)者更可能接种带状疱疹疫苗。
核心结论
- 需要进一步研究以了解带状疱疹疫苗接种的障碍。
- 增加有带状疱疹并发症风险者的资助资格或降低资格年龄可能提高疫苗覆盖率。
研究设计与样本
- 分析2019至2020年间开展的三项在线横断面调查的数据。
- 研究对象为居住在澳大利亚的65岁及以上成年人,样本共744人。
- 主要结局指标为自报的带状疱疹疫苗接种情况。
主要发现
- 744名65岁及以上参与者中32%报告接种过带状疱疹疫苗。
- 65-74岁参与者接种率为23%,75-84岁为55%,85岁及以上为0%。
- 接种季节性流感疫苗者接种带状疱疹疫苗的OR=4.41(95%CI:2.44-7.98),接种肺炎球菌疫苗者OR=4.43(95%CI:2.92-6.75)。
- 有卒中史者接种带状疱疹疫苗的OR=2.26(95%CI:1.13-4.49)。
- 每日吸烟者接种带状疱疹疫苗的OR=0.48(95%CI:0.26-0.89),偏好自然免疫者OR=0.29(95%CI:0.15-0.57),表达不信任疫苗者OR=0.34(95%CI:0.13-0.91)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以了解带状疱疹疫苗接种的障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE(S): To estimate HZ vaccine coverage in Australia among older Australians and to identify potential barriers to vaccination. DESIGN: Analysis of data from three cross-sectional surveys administered online between 2019 and 2020. SETTING AND PARTICIPANTS: Adults aged 65 and over residing in Australia. MAIN OUTCOME MEASURES: Self-reported herpes zoster vaccination. RESULTS: Among the 744 adults aged 65 and over in this sample, 32% reported being vaccinated for HZ, including 23% of participants aged 65-74, 55% of participants aged 75-84, and 0% for participants aged 85 and above. Those who are vaccinated with other immunisations are more likely to have received HZ vaccine, including seasonal influenza (OR = 4.41, 95 % CI: 2.44-7.98) and pneumococcal vaccines (OR = 4.43, 95 % CI: 2.92 - 6.75). Participants with a history of certain conditions, such as stroke (OR = 2.26, 95 % CI: 1.13-4.49), were more likely to be vaccinated against HZ. Participants that reported smoking tobacco daily were less likely to be vaccinated against HZ (OR = 0.48, 95 % CI: 0.26-0.89). Participants were less likely to be vaccinated against HZ if they preferred to develop immunity 'naturally' (OR = 0.29, 95 % CI: 0.15 - 0.57) or expressed distrust of vaccines (OR = 0.34, 95 % CI: 0.13-0.91). CONCLUSION(S): Further research is required to understand the barriers to HZ vaccine uptake. Increasing the funding eligibility for those who are at risk of complications from shingles, or lowering the age of eligibility, may increase vaccine coverage.
引用
- Ricks T, Trent MJ, MacIntyre CR, et al. Predictors of herpes zoster vaccination among Australian adults aged 65 and over. Vaccine. 2022. PMID: 36336528. doi:10.1016/j.vaccine.2022.10.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。